Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Recent clinical trials showed that expression of excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and thymidylate synthase (TS) proteins was able to predict the effects of non-small cell lung cancer (NSCLC) to chemotherapy. However, it remains unknown whether the adjuvant chemotherapy based on expression of the three proteins has survival significance in Chinese NSCLC patients.

Methods

We investigated 128 Chinese patients receiving chemotherapy after tumor resection for expression of these proteins using immunohistochemistry. Based on protein expression, patients were assigned to two groups for different adjuvant chemotherapy regimes. The disease-free survival (DFS) data were collected and analyzed using Kaplan–Meier curves and Cox models.

Results

We found that DFS of these patients with carboplatin and a third-generation agent (gemcitabine or pemetrexed) stratified by protein expression showed no statistical difference between individual treatment versus non-individuation treatment analyzed using Kaplan–Meier method (P = 0.143, median 23.9 vs. 30.8 months). Furthermore, the multivariate analysis showed that histology and tumor stages were independent predictors for DFS in these patients.

Conclusions

The results suggest that chemotherapy based on ERCC1, RRM1, and TS expression did not have significant impact on DFS of patients with resection of NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90

    Article  PubMed  Google Scholar 

  2. McCloskey P, Balduyck B, Van Schil PE, Faivre-Finn C, O’Brien M (2013) Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer 49(7):1555–1564

    Article  PubMed  Google Scholar 

  3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative G (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4):351–360

    Article  PubMed  Google Scholar 

  4. Geiger S, Schlemmer M, Heinemann V, Stemmler HJ (2010) Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all? Anticancer Drugs 21(9):799–804

    Article  CAS  PubMed  Google Scholar 

  5. Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Pechoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T (2010) Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 28(1):35–42

    Article  CAS  PubMed  Google Scholar 

  6. Filipits M, Pirker R (2011) Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer 74(3):355–363

    Article  PubMed  Google Scholar 

  7. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8(5):582–586

    CAS  PubMed  Google Scholar 

  8. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer G (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10(4):1318–1325

    Article  CAS  PubMed  Google Scholar 

  9. Rouquette I, Mazieres J (2011) A brief overview of a lung cancer biomarker: thymidylate synthase. Rev Mal Respir 28(6):773–777

    Article  CAS  PubMed  Google Scholar 

  10. Yokomise H, Liu D, Chang S, Go T, Ishikawa S, Misaki N, Nakashima N (2013) Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery. Anticancer Res 33(3):1107–1115

    PubMed  Google Scholar 

  11. Bergot E, Levallet G, Campbell K, Dubois F, Lechapt E, Zalcman G (2013) Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. Eur Respir Rev 22(130):565–576

    Article  PubMed  Google Scholar 

  12. Passaro A, Palazzo A, Trenta P, Mancini ML, Morano F, Cortesi E (2012) Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. Curr Med Chem 19(22):3689–3700

    Article  CAS  PubMed  Google Scholar 

  13. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98(9):1336–1343

    Article  CAS  PubMed  Google Scholar 

  14. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, Investigators IB (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991

    Article  CAS  PubMed  Google Scholar 

  15. Nicolson MC, Fennell DA, Ferry D, O’Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, Andre V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM (2013) Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol 8(7):930–939

    Article  CAS  PubMed  Google Scholar 

  16. Shimizu T, Nakanishi Y, Nakagawa Y, Tsujino I, Takahashi N, Nemoto N, Hashimoto S (2012) Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res 32(10):4589–4596

    CAS  PubMed  Google Scholar 

  17. Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR (2013) Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 31(19):2404–2412

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Besse B, Olaussen KA, Soria JC (2013) ERCC1 and RRM1: ready for prime time? J Clin Oncol 31(8):1050–1060

    Article  CAS  PubMed  Google Scholar 

  19. De Dosso S, Zanellato E, Nucifora M, Boldorini R, Sonzogni A, Biffi R, Fazio N, Bucci E, Beretta O, Crippa S, Saletti P, Frattini M (2013) ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother Pharmacol 72(1):159–165

    Article  CAS  PubMed  Google Scholar 

  20. Hubner RA, Riley RD, Billingham LJ, Popat S (2011) Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One 6(10):e25164

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, Andre F, Soria JC (2011) Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin Cancer Res 17(17):5562–5572

    Article  CAS  PubMed  Google Scholar 

  22. Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 8(12):e82241

    Article  PubMed Central  PubMed  Google Scholar 

  23. Lee SH, Noh KB, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kim CH, Kang KH, In KH (2013) Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer 81(1):102–108

    Article  PubMed  Google Scholar 

  24. Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, Cerny R, Pesek M (2012) Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res 32(11):5003–5010

    CAS  PubMed  Google Scholar 

  25. Olaussen KA, Mountzios G, Soria JC (2007) ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13(4):284–289

    Article  CAS  PubMed  Google Scholar 

  26. Seyhan EC, Altin S, Cetinkaya E, Sokucu S, Abali H, Buyukpinarbasili N, Fener N (2011) Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma. Ann Thorac Cardiovasc Surg 17(2):110–117

    Article  PubMed  Google Scholar 

  27. Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127(3):978–983

    Article  PubMed  Google Scholar 

  28. Sodja E, Knez L, Kern I, Ovcaricek T, Sadikov A, Cufer T (2012) Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer 48(18):3378–3385

    Article  CAS  PubMed  Google Scholar 

  29. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C, Patumanond J (2013) The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag Res 5:327–336

    Article  PubMed Central  PubMed  Google Scholar 

  30. Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D (2013) Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Lung Cancer 82(2):324–329

    Article  PubMed  Google Scholar 

  31. Yan D, Wei P, An G, Chen W (2013) Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. J Cardiothorac Surg 8:149

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Ozdemir O, Ozdemir P, Veral A, Uluer H, Ozhan MH (2013) ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac J Cancer Prev 14(8):4679–4683

    Article  PubMed  Google Scholar 

  33. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, Andre F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12):1101–1110

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Friboulet L, Postel-Vinay S, Sourisseau T, Adam J, Stoclin A, Ponsonnailles F, Dorvault N, Commo F, Saulnier P, Salome-Desmoulez S, Pottier G, Andre F, Kroemer G, Soria JC, Olaussen KA (2013) ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. Cell Cycle 12(20):3298–3306

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T (2001) Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37(13):1681–1687

    Article  CAS  PubMed  Google Scholar 

  36. Toffart AC, Timsit JF, Couraud S, Merle P, Moro-Sibilot D, Perol M, Mastroianni B, Souquet PJ, Girard N, Jeannin G, Romand P, Chatellain P, Vesin A, Brambilla C, Brambilla E (2014) Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). Lung Cancer 83(2):182–188

    Article  PubMed  Google Scholar 

  37. Zhang W, Guo N, Yu C, Wang H, Zhang Y, Xia H, Yu J, Lu J (2012) Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma. Tumour Biol 33(6):2209–2216

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, Filipits M, Chen Y, Kutok JL, Weaver DT, Ward BE, Soria JC (2012) Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 23(9):2245–2252

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the members of Lung Cancer Clinical Collaborative Research Group (Drs. Hai-hong Yang, Xia Gu, Xiang-lin Xiao, Fei Cui, Ya-lei Zhang, Hui Pan, Hui Xie, Wen-long Shao, and Gui-lin Peng) for their assistance in recruiting patients to this study.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Pharmacy, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    Yu-Wen He, Xin-Yun Yang & Qiu-Hua Deng

  2. Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, 151 Yanjiang Road, 510120, Guangzhou, China

    Mei-Ling Zhao & Jian-Xing He

  3. Department of Medical Genetics and Cell Biology, Guangzhou Medical University, Guangzhou, China

    Jun Zeng

Authors
  1. Yu-Wen He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mei-Ling Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xin-Yun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qiu-Hua Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jian-Xing He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-Xing He.

Additional information

Clinicaltrials.gov NCT 01781988.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, YW., Zhao, ML., Yang, XY. et al. Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer. Cancer Chemother Pharmacol 75, 861–867 (2015). https://doi.org/10.1007/s00280-015-2714-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2714-y

Keywords

Search

Navigation